Education
About Us
Working with TipRanks
Follow Us
NextCell Pharma AB (SE:NXTCL)
:NXTCL
NXTCL Stock Chart & Stats
kr0.92
kr0.02(0.56%)
At close: 4:00 PM EST
kr0.92
kr0.02(0.56%)
Day’s Range― - ―
52-Week Rangekr0.63 - kr3.84
Previous CloseN/A
Volume77.06K
Average Volume (3M)253.00K
Market Cap
kr76.08M
Enterprise ValueN/A
Total Cash (Recent Filing)kr38.72M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.48
Next Earnings
Jan 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding111,392,960
10 Day Avg. Volume177,013
30 Day Avg. Volume253,003
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.36
Price to Sales (P/S)8.24
P/FCF Ratio-2.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr141.27M
NXTCL FAQ
What was NextCell Pharma AB’s price range in the past 12 months?
NextCell Pharma AB lowest stock price was kr0.63 and its highest was kr3.84 in the past 12 months.
What is NextCell Pharma AB’s market cap?
NextCell Pharma AB’s market cap is kr76.08M.
When is NextCell Pharma AB’s upcoming earnings report date?
NextCell Pharma AB’s upcoming earnings report date is Jan 22, 2026 which is in 37 days.
How were NextCell Pharma AB’s earnings last quarter?
NextCell Pharma AB released its earnings results on Oct 30, 2025. The company reported -kr0.079 earnings per share for the quarter, beating the consensus estimate of -kr0.1 by kr0.021.
Is NextCell Pharma AB overvalued?
According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued.
Does NextCell Pharma AB pay dividends?
NextCell Pharma AB does not currently pay dividends.
What is NextCell Pharma AB’s EPS estimate?
NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NextCell Pharma AB have?
NextCell Pharma AB has 111,392,960 shares outstanding.
What happened to NextCell Pharma AB’s price movement after its last earnings report?
NextCell Pharma AB reported an EPS of -kr0.079 in its last earnings report, beating expectations of -kr0.1. Following the earnings report the stock price went up 0.787%.
Which hedge fund is a major shareholder of NextCell Pharma AB?
Currently, no hedge funds are holding shares in SE:NXTCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NextCell Pharma AB
NextCell Pharma AB (NXTCL) is a Swedish biopharmaceutical company focused on the development and commercialization of advanced therapies for immune-related diseases. The company specializes in stem cell-based treatments, with its flagship product, ProTrans, developed for the treatment of autoimmune conditions such as Type 1 Diabetes. NextCell Pharma operates within the biotechnology and healthcare sectors, aiming to leverage cutting-edge research to provide innovative therapeutic solutions.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Nanologica AB
―
Biovica International AB Class B
―
Modus Therapeutics Holding AB
―